Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.
Also called NCT06906081
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 100 participants
- Registry
-
NCT06906081 -
2024-516597-30-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Denmark
- Registry status
- Recruiting
Technical summary
Registry record NCT06906081. Randomized; quadruple masking; primary purpose treatment. Start 2025-05-02 (actual); primary completion 2028-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study
- Acronym
- FibroCAN
- Condition
- Cardiovascular Autonomic Neuropathy
- Condition
- Type 2 Diabetes
- Condition
- Diabetic Neuropathies
- Intervention (Drug)
- Kerendia (Finerenone, BAY94-8862)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Peter Rossing
- Collaborator
- Steno Diabetes Center Nordjylland
- Collaborator
- Aarhus University Hospital
Record details
- Record id
cardio:ct-nct06906081- Content hash
7f7eca9eef0c07ecb63858ce810cac6f615940ccc33409b96a457788cc0d9328